ResearcherUniversity of TurinActive in the last 2 years
Stefania Pizzimenti
Matched on ORCID iD 0000-0001-6937-8632; OpenAlex author ID A5043387826. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 3
2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 3
- Erratum to "Gemcitabine-loaded ICOS-Fc decorated nanosponges: a new chemo immunotherapy combination against pancreatic cancer". [Int. J. Pharm. 682 (2025) 1258… Co-author DOI 10.1016/j.ijpharm.2026.126582↗
- Gemcitabine-loaded ICOS-Fc decorated nanosponges: A new chemo immunotherapy combination against pancreatic cancer. Co-author DOI 10.1016/j.ijpharm.2025.125869↗
- Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells. Last author DOI 10.1016/j.freeradbiomed.2021.08.006↗
Closest collaborators
The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chiara Dianzani · 3 shared papers, 2021–2026 · strength 0.67
- Paper Erratum to "Gemcitabine-loaded ICOS-Fc decorated nanosponges: a new chemo immunotherapy combination against pancreatic … DOI 10.1016/j.ijpharm.2026.126582↗
- Paper Gemcitabine-loaded ICOS-Fc decorated nanosponges: A new chemo immunotherapy combination against pancreatic cancer. DOI 10.1016/j.ijpharm.2025.125869↗
- Paper Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresi… DOI 10.1016/j.freeradbiomed.2021.08.006↗
- Monica Argenziano · 2 shared papers, 2025–2026 · strength 0.52
- Paper Erratum to "Gemcitabine-loaded ICOS-Fc decorated nanosponges: a new chemo immunotherapy combination against pancreatic … DOI 10.1016/j.ijpharm.2026.126582↗
- Paper Gemcitabine-loaded ICOS-Fc decorated nanosponges: A new chemo immunotherapy combination against pancreatic cancer. DOI 10.1016/j.ijpharm.2025.125869↗
- Margherita Grattarola · 1 shared paper, 2021 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.